Assessment of Serum High Sensitive C-Reactive Protein Level among Patients with Metabolic Syndrome – Khartoum State

Abstract

Worldwide prevalence of metabolic syndrome (MetS) is widely diverse, ranges from <10% to 84%. MetS is associated with increased Cardiovascular disease (CVD) mortality. Elevated levels of high-sensitivite C-reactive protein (Hs-CRP) are associated with increased risk for CVD, this study aimed to assess serum level of High-sensitive C-reactive protein in patients with MetS. This case control study was carried out in Abdalla Khalil center and Mahdi center, in Khartoum state, during the period from April 2019 to November 2020. A total of 66 participants were enrolled in this study, 33 of them were MetS patients as case (16 male and 17 female) and 33 healthy individuals as control (16 male and 17 female), age was matched in both groups. Serum Hs-CRP levels were estimated by using FIA meter. Data were analyzed using SPSS computer program. The level of Hs-CRP was significantly increased in MetS patients (20.7 ± 14.8) compared to control group (6.38±1.38) with P-value 0.000. According to age Hs-CRP level was insignificantly differ in patients who were < 50 years when compared to those who were > 50 years (22.75 ± 15.47 and 18.78 ± 14.34) respectively, with P-value 0.452. According to gender Hs-CRP level was insignificantly differ in females (23.76 ± 14.56) compared to males (17.46 ± 14.8) with P-value 0.227. According to BMI Hs-CRP level was insignificantly differ in obese patients (≥ 30 Kg/m2) compared to overweight patients (25-29.9 Kg/m2) (21.1 ± 12.1 and 20.4 ± 17.04) respectively, with P-value 0.162. According to therapy usage Hs-CRP level was significantly decreased in patients who were using lipid-lowering drugs compared to patients who were not (13.5 ± 8.6 and 24.8 ± 16.2) respectively, with P-value (0.014), but it was insignificantly differ in patients who were using glucose-lowering drugs or not (17.7 ± 12.9 vs. 24.2 ± 16.6), and those who were using blood pressure-lowering drug drugs or not (23.1 ± 17.1 vs. 18.1 ± 11.9), with P-value (0.216 and 0.351) respectively. There was no correlation between the level of Hs-CRP and both of BMI and WC with (r = 0.079 and -0.118) respectively, but there was +ve, weak and significant correlation between BMI and WC with (r = 0.475). MetS patients had increased Hs-CRP levels which might be associated with increased risk of CVD.